Brain targeting effect of camptothecin-loaded solid lipid nanoparticles in rat after intravenous administration

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 85, Issue 3 PART A, 2013, Pages 488-502

  Martins, Susana M ^a,b   Sarmento, Bruno ^a,c,d   Nunes, Cláudia ^a   Lúcio, Marlene ^a   Reis, Salette ^a   Ferreira, Domingos C ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c UNIVERSITY INSTITUTE OF HEALTH SCIENCES IUCS   (Portugal)

^d INEB INSTITUTO DE ENGENHARIA BIOMÉDICA   (Portugal)

Author keywords

Biodistribution; Brain targeting; Camptothecin; Cytotoxicity; DMPC membrane bilayer model; Gliomas; Polysorbates; Solid lipid nanoparticles (SLN)

Indexed keywords

CAMPTOTHECIN; SOLID LIPID NANOPARTICLE;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; CELL DEATH; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG TARGETING; ENCAPSULATION; GLIOMA; HUMAN; HUMAN CELL; IC 50; MACROPHAGE; MALE; MEAN RESIDENCE TIME; NONHUMAN; PARENCHYMA; RADIATION SCATTERING; RAT; SURFACE CHARGE; SYNCHROTRON; WIDE ANGLE X RAY SCATTERING; X RAY CRYSTALLOGRAPHY;

1,2-DIMYRISTOYL-SN-GLYCERO-3-PHOSPHO-CHOLINE; APO E; APOLIPOPROTEIN E; BIODISTRIBUTION; BRAIN TARGETING; CAMPTOTHECIN; CENTRAL NERVOUS SYSTEM; CNS; CYTOTOXICITY; DMEM; DMPC; DMPC MEMBRANE BILAYER MODEL; DULBECCO'S MODIFIED EAGLE'S MEDIUM; FBS; FETAL BOVINE SERUM; GLIOMAS; HANKS' BALANCED SALT SOLUTION; HBSS; LDL; LOW-DENSITY LIPOPROTEIN; PBCA; POLYBUTYLCYANOACRYLATE; POLYSORBATES; SAXS/WAXS; SCANNING ELECTRON MICROSCOPY; SEM; SLN; SOLID LIPID NANOPARTICLES; SOLID LIPID NANOPARTICLES (SLN); SYNCHROTRON SMALL AND WIDE ANGLE X-RAY SCATTERING;

ADMINISTRATION, INTRAVENOUS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOOD-BRAIN BARRIER; BRAIN; BRAIN NEOPLASMS; CAMPTOTHECIN; CELL LINE; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; GLIOMA; HUMANS; INHIBITORY CONCENTRATION 50; LIPIDS; MACROPHAGES; MALE; NANOPARTICLES; PARTICLE SIZE; RATS; RATS, WISTAR; SCATTERING, SMALL ANGLE; TISSUE DISTRIBUTION;

EID: 84888387689     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2013.08.011     Document Type: Article

References (82)

1. D.N. Louis F.T. Bosman, WHO Classification of Tumours of the Central Nervous System 2007 International Agency for Research on Cancer (IARC) Lyon
2. A.S. Darefsky, J.T. King, Jr., R. Dubrow, Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of surveillance, epidemiology, and end results registries. Cancer, 2011.
3. W.M. Pardridge Alzheimer's disease drug development and the problem of the blood-brain barrier Alzheimers Dement. 5 2009 427 432
4. I. Reimold Delivery of nanoparticles to the brain detected by fluorescence microscopy Eur. J. Pharm. Biopharm. 70 2008 627 632
5. P. Botella Surface-modified silica nanoparticles for tumor-targeted delivery of camptothecin and its biological evaluation J. Control. Release 156 2011 246 257
6. S. Wohlfart, S. Gelperina, and J. Kreuter Transport of drugs across the blood-brain barrier by nanoparticles J. Control. Release 2011
7. Y. Cirpanli Antitumoral activity of camptothecin-loaded nanoparticles in 9L rat glioma model Int. J. Pharm. 403 2011 201 206
8. P.B. Storm Polymer delivery of camptothecin against 9L gliosarcoma: release, distribution, and efficacy J. Neuro-Oncol. 56 2002 209 217
9. Y.C. Kuo, and C.T. Liang Inhibition of human brain malignant glioblastoma cells using carmustine-loaded catanionic solid lipid nanoparticles with surface anti-epithelial growth factor receptor Biomaterials 32 2011 3340 3350
10. M.L. Bondi Brain-targeted solid lipid nanoparticles containing riluzole: preparation, characterization and biodistribution Nanomedicine (London) 5 2010 25 32
11. I.P. Kaur Potential of solid lipid nanoparticles in brain targeting J. Control. Release 127 2008 97 109
12. P. Blasi Solid lipid nanoparticles for targeted brain drug delivery Adv. Drug Deliv. Rev. 59 2007 454 477
13. J. Kreuter Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles) Brain Res. 674 1995 171 174
14. X.H. Tian Enhanced brain targeting of temozolomide in polysorbate-80 coated polybutylcyanoacrylate nanoparticles Int. J. Nanomed. 6 2011 445 452
15. C.X. Wang Antitumor effects of polysorbate-80 coated gemcitabine polybutylcyanoacrylate nanoparticles in vitro and its pharmacodynamics in vivo on C6 glioma cells of a brain tumor model Brain Res. 1261 2009 91 99
16. B. Wilson Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles Eur. J. Pharm. Biopharm. 70 2008 75 84
17. K. Gao, and X. Jiang Influence of particle size on transport of methotrexate across blood brain barrier by polysorbate 80-coated polybutylcyanoacrylate nanoparticles Int. J. Pharm. 310 2006 213 219
18. R.H. Müller, et al., Production of Biofunctionalized Solid Lipid Nanoparticles for Site-specific Drug Delivery, Nanotechnologies for the Life Sciences 2007, Wiley-VCH Verlag GmbH & Co. KGaA, 2007.
19. J. Kreuter Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier J. Drug Target. 10 2002 317 325
20. J. Kreuter Influence of the surface properties on nanoparticle-mediated transport of drugs to the brain J. Nanosci. Nanotechnol. 4 2004 484 488
21. J. Kreuter Nanoparticulate systems for brain delivery of drugs Adv. Drug Deliv. Rev. 47 2001 65 81
22. A. Zensi Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones J. Control. Release 137 2009 78 86
23. U. Hanke Commonly used nonionic surfactants interact differently with the human efflux transporters ABCB1 (p-glycoprotein) and ABCC2 (MRP2) Eur. J. Pharm. Biopharm. 76 2010 260 268
24. G. Cornaire Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo Int. J. Pharm. 278 2004 119 131
25. M.E. Wall Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumour inhibitor from Camptotheca acuminata J. Am. Chem. Soc. 88 1966 3888 3890
26. B.C. Giovanella Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin Cancer Res. 51 1991 3052 3055
27. M. Potmesil Camptothecins: from bench research to hospital wards Cancer Res. 54 1994 1431 1439
28. L.F. Liu Mechanism of action of camptothecin Ann. N. Y. Acad. Sci. 922 2000 1 10
29. V.K. Puduvalli Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme Neuro Oncol. 10 2008 216 222
30. M. Santisteban Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results J. Neuro-Oncol. 92 2009 165 175
31. B.C. Giovanella Dependence of anticancer activity of camptothecins on maintaining their lactone function Ann. N. Y. Acad. Sci. 922 2000 27 35
32. L.P. Rivory, and J. Robert Molecular, cellular, and clinical aspects of the pharmacology of 20(S)camptothecin and its derivatives Pharmacol. Ther. 68 1995 269 296
33. H. Cabral A photo-activated targeting chemotherapy using glutathione sensitive camptothecin-loaded polymeric micelles Pharm. Res. 26 2009 82 92
34. F. Cengelli Surface-functionalized ultrasmall superparamagnetic nanoparticles as magnetic delivery vectors for camptothecin ChemMedChem 4 2009 988 997
35. Z.R. Huang Development and evaluation of lipid nanoparticles for camptothecin delivery: a comparison of solid lipid nanoparticles, nanostructured lipid carriers, and lipid emulsion Acta Pharmacol. Sin. 29 2008 1094 1102
36. S. Yang Body distribution of camptothecin solid lipid nanoparticles after oral administration Pharm. Res. 16 1999 751 757
37. S.C. Yang Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain J. Control. Release 59 1999 299 307
38. S.C. Yang, and J.B. Zhu Preparation and characterization of camptothecin solid lipid nanoparticles Drug Dev. Ind. Pharm. 28 2002 265 274
39. M.D. Joshi, and R.H. Muller Lipid nanoparticles for parenteral delivery of actives Eur. J. Pharm. Biopharm. 71 2009 161 172
40. S. Martins Physicochemical properties of lipid nanoparticles: effect of lipid and surfactant composition Drug Dev. Ind. Pharm. 37 2011 815 824
41. S.M. Martins Development and validation of a simple reversed-phase HPLC method for the determination of camptothecin in animal organs following administration in solid lipid nanoparticles J. Chromatogr. B 880 2012 100 107
42. M.E. Fox Synthesis and in vivo antitumor efficacy of PEGylated poly(l-lysine) dendrimer-camptothecin conjugates Mol. Pharm. 6 2009 1562 1572
43. C.u. Nunes Synchrotron SAXS and WAXS study of the interactions of NSAIDs with lipid membranes J. Phys. Chem. B 115 2011 8024 8032
44. T. Mosmann Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays J. Immunol. Methods 65 1983 55 63
45. T. Nomura Effect of particle size and charge on the disposition of lipid carriers after intratumoral injection into tissue-isolated tumors Pharm. Res. 15 1998 128 132
46. R.H. Müller, C. Jacobs, and O. Kayser Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future Adv. Drug Deliv. Rev. 47 2001 3 19
47. P.R. Lockman Nanoparticle surface charges alter blood-brain barrier integrity and permeability J. Drug Target. 12 2004 635 641
48. R. Kedmi, N. Ben-Arie, and D. Peer The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation Biomaterials 31 2010 6867 6875
49. A.M. Sætern Effect of hydroxypropyl-β-cyclodextrin- complexation and pH on solubility of camptothecin Int. J. Pharm. 284 2004 61 68
50. P. Shahgaldian Para-acyl-calix-arene based solid lipid nanoparticles (SLNs): a detailed study of preparation and stability parameters Int. J. Pharm. 253 2003 23 38
51. H. Bunjes, and T. Unruh Characterization of lipid nanoparticles by differential scanning calorimetry, X-ray and neutron scattering Adv. Drug Deliv. Rev. 59 2007 379 402
52. K. Larsson Classication of glyceride crystal forms Acta Chem. Scand. 20 1966 2255 2260
53. S. Martins Brain delivery of camptothecin by means of solid lipid nanoparticles: formulation design, in vitro and in vivo studies Int. J. Pharm. 439 2012 49 62
54. R.H. Muller, K. Mader, and S. Gohla Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art Eur. J. Pharm. Biopharm. 50 2000 161 177
55. R.H. Muller, M. Radtke, and S.A. Wissing Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations Adv. Drug Deliv. Rev. 54 2002 S131 S155
56. R. Koynova, B. Tenchov, and G. Rapp Low amounts of PEG-lipid induce cubic phase in phosphatidylethanolamine dispersions Biochim. Biophys. Acta - Biomembranes 1326 1997 167 170
57. P.T. Spicer Progress in liquid crystalline dispersions: cubosomes Curr. Opin. Colloid Interface Sci. 10 2005 274 279
58. M. Kozak The FTIR and SAXS studies of influence of a morpholine derivatives on the DMPC-based biological membrane systems Radiat. Phys. Chem. 78 2009 S129 S133
59. J. Lin Penetration of lipid membranes by gold nanoparticles: insights into cellular uptake, cytotoxicity, and their relationship ACS Nano 4 2010 5421 5429
60. C.V. Kelly Poly(amidoamine) dendrimers on lipid bilayers II: Effects of bilayer phase and dendrimer termination J. Phys. Chem. B 112 2008 9346 9353
61. W.F. Hickey Leukocyte traffic in the central nervous system: the participants and their roles Semin. Immunol. 11 1999 125 137
62. S.-K. Baek Photothermal treatment of glioma; an in vitro study of macrophage-mediated delivery of gold nanoshells J. Neuro-Oncol. 104 2011 439 448
63. X. Shan Influence of PEG chain on the complement activation suppression and longevity in vivo prolongation of the PCL biomedical nanoparticles Biomed. Microdevices 11 2009 1187 1194
64. S. Martins Solid lipid nanoparticles as intracellular drug transporters: an investigation of the uptake mechanism and pathway Int. J. Pharm. 430 2012
65. W. Wei Lipid nanoparticles loaded with 10-hydroxycamptothecin- phospholipid complex developed for the treatment of hepatoma in clinical application J. Drug Target. 18 2010 557 566
66. B. Arechabala Comparison of cytotoxicity of various surfactants tested on normal human fibroblast cultures using the neutral red test, MTT assay and LDH release J. Appl. Toxicol. 19 1999 163 165
67. S.-W. Wang Determination of P-glycoprotein inhibition by excipients and their combinations using an integrated high-throughput process J. Pharm. Sci. 93 2004 2755 2767
68. A. Estella-Hermoso de Mendoza In vitro and in vivo efficacy of edelfosine-loaded lipid nanoparticles against glioma J. Control. Release 156 2011 421 426
69. I. van Rooy In vivo methods to study uptake of nanoparticles into the brain Pharm. Res. 28 2011 456 471
70. W. Banks Developing drugs that can cross the blood-brain barrier: applications to Alzheimer's disease BMC Neurosci. Suppl. 9 3 2008 S2
71. A. Misra Drug delivery to the central nervous system: a review J. Pharm. Pharm. Sci. 6 2003 252 273
72. W. Mehnert, and K. Mäder Solid lipid nanoparticles: production, characterization and applications Adv. Drug Deliv. Rev. 47 2001 165 196
73. K. Etschmaier Adipose triglyceride lipase affects triacylglycerol metabolism at brain barriers J. Neurochem. 119 2011 1016 1028
74. É. Paradis Lipoprotein lipase and endothelial lipase expression in mouse brain: regional distribution and selective induction following kainic acid-induced lesion and focal cerebral ischemia Neurobiol. Dis. 15 2004 312 325
75. K. Haverstick, A. Fleming, and W.M. Saltzman Conjugation to increase treatment volume during local therapy: a case study with PEGylated camptothecin Bioconjug. Chem. 18 2007 2115 2121
76. G.L. Beretta, and F. Zunino Relevance of extracellular and intracellular interactions of camptothecins as determinants of antitumor activity Biochem. Pharmacol. 74 2007 1437 1444
77. M. Gaumet Nanoparticles for drug delivery: the need for precision in reporting particle size parameters Eur. J. Pharm. Biopharm. 69 2008 1 9
78. A.K. Jain The effect of the oral administration of polymeric nanoparticles on the efficacy and toxicity of tamoxifen Biomaterials 32 2011 503 515
79. J. Kreuter Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the blood-brain barrier using surfactant-coated nanoparticles J. Control. Release 49 1997 81 87
80. F. Alexis Factors affecting the clearance and biodistribution of polymeric nanoparticles Mol. Pharm. 5 2008 505 515
81. D.O. Scott Urinary and biliary disposition of the lactone and carboxylate forms of 20(S)-camptothecin in rats Drug Metab. Dispos. 22 1994 438 442
82. S.M. Moghimi, A.C. Hunter, and J.C. Murray Long-circulating and target-specific nanoparticles: theory to practice Pharmacol. Rev. 53 2001 283 318